midterms
Affordability eats MAHA
In last week’s newsletter, I told you about Democratic efforts to win back MAHA voters. The bigger question is whether the movement will survive the midterms, according to Isa Cueto, Chelsea Cirruzzo, and Daniel Payne.
MAHA frontman Robert F. Kennedy Jr. is one of President Trump’s most popular cabinet members, and the health secretary has been a campaign surrogate all over the country. Kennedy’s critiques of the American food supply and corporate influence continue to have widespread appeal.
Yet the movement is nearly invisible in midterm campaigns. Some candidates who are all in on MAHA have fared poorly. Many voters are more worried about losing food assistance than eating healthy, and it’s hard to care about pricey wearables and experimental peptides when you can’t afford health insurance.
Meanwhile, corporations are insinuating themselves into MAHA’s inner circle.
Read more about why the very soul of MAHA might be at stake come Nov. 3.
Medicare advantage
The stars did not align for Alignment
Bob Herman gives a rundown of the new quality ratings for Medicare Advantage insurers, called star ratings.
There’s deep uncertainty, and a lot of money at stake, around Medicare Advantage quality measures.
Nearly 71% of seniors are enrolled in plans with ratings high enough to get the largest possible bonus next year. That’s up from 68% this year.
But some companies fell below that threshold. One company, Alignment Healthcare, has already threatened to sue the government after its ratings downgrade.
Read more about the winners and losers.
hospitals
The more things change…
The last time the Trump administration tried to overhaul the 340B drug discount program for safety-net hospitals, the American Hospital Association sued to block the pilot. A federal judge temporarily halted it, and HHS withdrew the plan after losing on appeal.
In February, the agency announced another version of the pilot that would target 25 of the costliest, most widely used drugs covered under Medicare.
The AHA is suing again.
Read more from Tara Bannow about what’s different this time, and what’s the same.